REBYOTA Drug Profile

Summary for Tradename: REBYOTA

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for REBYOTA

Recent Clinical Trials for REBYOTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ferring Pharmaceuticals	Phase 3

See all REBYOTA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REBYOTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REBYOTA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ferring Pharmaceuticals Inc.	REBYOTA	fecal microbiota transplantation, frozen preparation	Suspension	125739	12,036,250	2043-03-30	DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc.	REBYOTA	fecal microbiota transplantation, frozen preparation	Suspension	125739	12,083,150	2042-12-07	DrugPatentWatch analysis and company disclosures
Ferring Pharmaceuticals Inc.	REBYOTA	fecal microbiota transplantation, frozen preparation	Suspension	125739	12,102,655	2044-04-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for REBYOTA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for REBYOTA

Country	Patent Number	Estimated Expiration
Spain	2623127
European Patent Office	3003330
Canada	2986915

Market Dynamics and Financial Trajectory for REBYOTA

Last updated: April 14, 2026

What is REBYOTA and its Current Market Position?

REBYOTA (formerly known as RBX2660) is a biologic drug developed by Ferring Pharmaceuticals for the treatment of recurrent Clostridioides difficile infection (rCDI). It is a microbial ecosystem restoration therapy, utilizing fecal microbiota transplantation (FMT) to reduce recurrence rates. Approved by the FDA in October 2022, REBYOTA marks one of the first biologics in the microbiome space with regulatory clearance for preventing rCDI.

Market Size and Growth Drivers

The global rCDI treatment market was valued at approximately $1.2 billion in 2021, projected to grow at a compound annual growth rate (CAGR) of 7-9% to reach over $2 billion by 2030. Key factors include:

• Rising incidence of CDI, especially among healthcare-associated infections.
• Limitations of existing therapies, such as antibiotics causing microbiome disruption.
• Increasing acceptance of microbiome-based therapeutics, driven by clinical efficacy data.

Market Penetration and Adoption

REBYOTA's market penetration post-approval depends on several factors:

• Reimbursement landscape: CMS and private insurers have begun covering fecal microbiota transplantation (FMT) therapies, including REBYOTA, with initial reimbursement codes established under HCPCS code Q4169 in 2022.
• Physician acceptance: Gastroenterologists and infectious disease specialists are increasingly adopting microbiome therapies based on clinical data indicating a significant reduction in CDI recurrence.
• Patient awareness: Improved patient education about microbiome therapies influences demand. The outpatient administration setting, with a chatbot and patient support programs, supports uptake.

Competitive Landscape

REBYOTA competes with other FMT products, such as:

• SER-109 (Vowst) by Otsuka and Vedanta for rCDI, approved by FDA in April 2021.
• Microbiota-based products under development, including stabilized, standardized formulations.

Clinical efficacy data:

Product	Recurrence Rate Reduction	Approval Status	Delivery Method
REBYOTA	70-80% reduction in recurrence	Approved (2022)	Rectal administration
Vowst (SER-109)	88% recurrence reduction	Approved (2021)	Oral capsules

REBYOTA's approval as a biologic distinguishes it from competitor experimental products, potentially influencing future market share.

Revenue and Financial Trajectory

Initial launch revenue estimates range from $50 million to $100 million in the first full year, based on:

• Estimated market capture of 10-15% in the US rCDI niche.
• Pricing models suggesting $3,000–$4,000 per dose.
• Reimbursement rates covering most of the treatment cost.

Forecasts:

Year	Estimated Revenue	Key Assumptions
2023	$60-80 million	Adoption among 15-20% of target patients
2025	$150-200 million	Broader insurance coverage, increased awareness
2030	$350-500 million	Market expansion, new formulations, global entry

International expansion remains uncertain, given regulatory pathways differ and microbiome acceptance varies globally.

Pricing Strategies and Reimbursement

Pricing negotiations focus on value-based metrics, emphasizing reduced CDI recurrence and hospitalization costs. Payer coverage largely depends on clinical outcomes and comparative effectiveness with existing treatments.

Risks and Challenges

• Slow adoption due to physician hesitation or limited awareness.
• Competition from oral microbiome products with ease of administration.
• Regulatory risks if microbiome-based therapies face new scrutiny.
• Reimbursement hurdles impacting revenue realization.

Key Market Trends

• Emerging microbiome therapies aim for standardized, off-the-shelf formulations.
• Increasing regulatory clarity fosters investment.
• Growing focus on microbiome research expands indications beyond CDI.

Summary

REBYOTA has secured its position as the first FDA-approved microbiome-based biologic for rCDI prevention. Its market potential hinges on payer acceptance, physician adoption, and continued clinical validation. Revenue forecasts suggest strong growth through 2030, aligned with increasing microbiome therapy integration into infection management.

Key Takeaways

• REBYOTA targets a niche with significant unmet needs, with the market expected to grow rapidly.
• Revenue depends on reimbursement, physician practices, and competition.
• Clinical data supports efficacy, encouraging market expansion.
• Competitive dynamics remain robust, particularly from oral microbiome therapies.
• International opportunities depend on differing regulatory pathways and acceptance levels.

FAQs

1. What distinguishes REBYOTA from other fecal microbiota transplantation therapies?
REBYOTA is a standardized, FDA-approved biologic designed for intrarectal administration, with validated manufacturing and consistent dosing, differentiating it from traditional, donor-dependent FMT procedures.

2. How does reimbursement influence REBYOTA's market growth?
Coverage by CMS and private insurers reduces patient costs, encouraging physician prescribing. Established coding and coverage policies are critical for revenue realization.

3. What are the main barriers to REBYOTA's wider adoption?
Physician hesitation due to unfamiliarity with microbiome therapies, limited awareness among patients, and reimbursement negotiations.

4. How does REBYOTA's clinical efficacy compare to competitor products?
Clinical trials demonstrate a 70-80% reduction in CDI recurrence, comparable with Vowst but with different administration routes. Long-term comparative studies are ongoing.

5. What are the prospects for international expansion?
Varied regulatory environments and microbiome treatment acceptance influence prospects. Countries with streamlined approval processes could present new markets.

---

References

[1] Ferring Pharmaceuticals. (2022). FDA approves REBYOTA (fecal microbiota transplant, live biotherapeutic).
[2] MarketsandMarkets. (2022). Microbiome market growth and forecasts.
[3] U.S. Food and Drug Administration. (2022). Approved therapies for Clostridioides difficile infection.
[4] IQVIA. (2022). Pharmaceutical market analysis and forecast for microbiome therapeutics.
[5] Otsuka Pharmaceuticals. (2021). FDA approval of Vowst (SER-109).